Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?

<h4>Background</h4> The growing burden of diabetes worldwide is a threat to tuberculosis (TB) control. Drug-induced liver injury (DILI) due to TB drugs is a significant concern and there is currently limited evidence on the effect of diabetes on TB DILI. This study sought to investigate...

Full description

Bibliographic Details
Main Authors: Ivanice D. Freire, Katherine L. Fielding, David A. J. Moore
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231779/?tool=EBI
_version_ 1797812038148292608
author Ivanice D. Freire
Katherine L. Fielding
David A. J. Moore
author_facet Ivanice D. Freire
Katherine L. Fielding
David A. J. Moore
author_sort Ivanice D. Freire
collection DOAJ
description <h4>Background</h4> The growing burden of diabetes worldwide is a threat to tuberculosis (TB) control. Drug-induced liver injury (DILI) due to TB drugs is a significant concern and there is currently limited evidence on the effect of diabetes on TB DILI. This study sought to investigate the effect of diabetes as a risk factor for DILI and to further study any potential co-factors. <h4>Methods</h4> An unmatched case-control study. Cases were TB patients on 2RHZE/4RH presenting with DILI from 2013–2017 in Porto Alegre, Brazil. Controls were contemporaneous TB patients without DILI being treated in any one of the same five Porto Alegre TB clinics. The exposure variables were diabetes (main exposure variable), age, sex, alcohol misuse, human immunodeficiency virus (HIV), hepatitis C (HCV) and B (HBV) viruses, concomitant hepatotoxic drugs, other liver diseases and TB site. The outcome variable was the occurrence of DILI. <h4>Results</h4> Odds of DILI were increased by: older age group 51–60, 61–70 and 71–93 years (adjusted OR 2.39, 95%CI 1.30–4,38; adjusted OR 4.37, 2.28–8,35; adjusted OR 12.91, 5.81–28,66, respectively), HIV positive status (adjusted OR 3.59, 95%CI 2.25–5.73), HCV positive status (adjusted OR 3.49, 95%CI 1.96–6.21) and having concurrent pulmonary and extrapulmonary TB (adjusted OR 3.16, 95%CI 1.93–5.19). Diabetes, gender, and other hepatotoxic drugs were not associated with DILI. <h4>Conclusions</h4> This study confirms the association between TB DILI and well-known risk factors but did not demonstrate increased odds of TB DILI in patients with diabetes.
first_indexed 2024-03-13T07:32:38Z
format Article
id doaj.art-83b91924be2e43f599147c886364eeca
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-03-13T07:32:38Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-83b91924be2e43f599147c886364eeca2023-06-04T05:32:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01185Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?Ivanice D. FreireKatherine L. FieldingDavid A. J. Moore<h4>Background</h4> The growing burden of diabetes worldwide is a threat to tuberculosis (TB) control. Drug-induced liver injury (DILI) due to TB drugs is a significant concern and there is currently limited evidence on the effect of diabetes on TB DILI. This study sought to investigate the effect of diabetes as a risk factor for DILI and to further study any potential co-factors. <h4>Methods</h4> An unmatched case-control study. Cases were TB patients on 2RHZE/4RH presenting with DILI from 2013–2017 in Porto Alegre, Brazil. Controls were contemporaneous TB patients without DILI being treated in any one of the same five Porto Alegre TB clinics. The exposure variables were diabetes (main exposure variable), age, sex, alcohol misuse, human immunodeficiency virus (HIV), hepatitis C (HCV) and B (HBV) viruses, concomitant hepatotoxic drugs, other liver diseases and TB site. The outcome variable was the occurrence of DILI. <h4>Results</h4> Odds of DILI were increased by: older age group 51–60, 61–70 and 71–93 years (adjusted OR 2.39, 95%CI 1.30–4,38; adjusted OR 4.37, 2.28–8,35; adjusted OR 12.91, 5.81–28,66, respectively), HIV positive status (adjusted OR 3.59, 95%CI 2.25–5.73), HCV positive status (adjusted OR 3.49, 95%CI 1.96–6.21) and having concurrent pulmonary and extrapulmonary TB (adjusted OR 3.16, 95%CI 1.93–5.19). Diabetes, gender, and other hepatotoxic drugs were not associated with DILI. <h4>Conclusions</h4> This study confirms the association between TB DILI and well-known risk factors but did not demonstrate increased odds of TB DILI in patients with diabetes.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231779/?tool=EBI
spellingShingle Ivanice D. Freire
Katherine L. Fielding
David A. J. Moore
Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
PLoS ONE
title Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
title_full Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
title_fullStr Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
title_full_unstemmed Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
title_short Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
title_sort does diabetes mellitus comorbidity increase the risk of drug induced liver injury during tuberculosis treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231779/?tool=EBI
work_keys_str_mv AT ivanicedfreire doesdiabetesmellituscomorbidityincreasetheriskofdruginducedliverinjuryduringtuberculosistreatment
AT katherinelfielding doesdiabetesmellituscomorbidityincreasetheriskofdruginducedliverinjuryduringtuberculosistreatment
AT davidajmoore doesdiabetesmellituscomorbidityincreasetheriskofdruginducedliverinjuryduringtuberculosistreatment